Cordex Pharma Sets Fourth Quarter 2008 Program U...( Conference call scheduled for Friday ...),Health
Conference call scheduled for Friday, February 20, at 10:00 a.m. EST
LA JOLLA, Calif., Feb. 13 /PRNewswire-FirstCall/ -- Cordex Pharma, Inc. (OTC Bulletin Board: CDXP) will host a teleconference on Friday, February 20, at 10:00 a.m. EST to provide a fourth quarter business review and drug development update. Cordex's Chief Executive Officer, James S. Kuo, M.D., M.B.A., will give the presentation and there will be a question-and-answer session immediately afterwards.
To participate in the teleconference, please call toll-free 800.894.5910 (direct dial 785.424.1052) five minutes prior to the scheduled starting time in order to register for the call.
A replay of the call will be available after the call's completion for ten days at 800.283.8520 (direct dial 402.220.0870).
About Cordex Pharma, Inc.
Cordex is a specialty pharmaceutical company that develops new cardiovascular medicines based upon the emerging pharmacology of adenosine triphosphate (ATP) and nitric oxide (NO). These two molecules play critical roles in cellular metabolism and signal transduction, the manipulation of which constitute novel therapeutic modalities for the treatment of major cardiovascular disorders. Cordex has a portfolio of investigational medicines, two of which are in late stages of clinical development. Cordex's ATPace is expected to enter a Phase 3 clinical trial for the treatment of paroxysmal supraventricular tachycardia in 2009. Cordex's CDP-1050 is also expected to commence a Phase 2 clinical trial for the treatment of heart failure in 2009. In addition, Cordex has a preclinical program to develop new chemical entities that target a recently discovered pathway in the pathophysiology of chronic obstructive pulmonary disease. For further information regarding Cordex, please visit the company's website at www.cordexpharma.com.
Forw
'/>"/>
| SOURCE Cordex Pharma, Inc. Copyright©2009 PR Newswire. All rights reserved |
Related medicine news :
1. Combination Products Executive Forum to be Hosted by CHI's Pharmaceutical Strategy Series
2. Onyx Pharmaceuticals Announces Fourth Quarter and Full Year 2008 Financial Results Teleconference and Webcast
3. Union Springs Pharmaceuticals Introduces New, More Effective Respirator
4. URAC Calls for Public Comment on Revisions to its Pharmacy Benefit Management (PBM) and Drug Therapy Management (DTM), Version 2.0 Standards and NEW Performance Measures, and PHARM Core, Version 3.0 Standards
5. Shengtai Pharmaceutical Schedules 2009 Second Quarter Financial Results and Conference Call
6. ISTA Pharmaceuticals Announces Conference Call and Webcast of Fourth Quarter and Full-Year 2008 Financial Results
7. Managing Myeloma (www.managingmyeloma.com) Launches - A Comprehensive Information and Educational Site for Physicians, Nurse Practitioners, Physician Assistants, and Pharmacists
8. Otsuka America Pharmaceutical, Inc. Announces the Appointment of Mark Altmeyer as President and Chief Executive Officer
9. DOR BioPharma Announces Potential $30 Million North American Partnership Agreement with Sigma-Tau Pharmaceuticals for orBec(R) in the Treatment of Graft-versus-Host Disease
10. Portola Pharmaceuticals Enters Worldwide License Agreement for Development and Commercialization of Novel Antiplatelet Drug Elinogrel
11. Valeant Pharmaceuticals to Announce 2008 Fourth Quarter and Year Results on February 24, 2009
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |